Owlstone Medical

The breath biomarker panel, which is now commercially available, is intended to support research to distinguish between different types of chronic inflammatory airway diseases including asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis, and to facilitate better therapeutic decision making and monitoring.

The consortium aims to further elucidate the complex relationships between environment and disease by developing the concept of the ‘working-life exposome’, which takes into account all occupational and related non-occupational exposures (e.g. lifestyle) throughout the lifespan of an individual.

The collaboration seeks to advance the application of non-invasive breath sampling to address the challenges of the early detection of disease and the precision medicine delivery of healthcare through the discovery and validation of novel biomarkers

3/28/18: Commercially available research kits extend access to Breath Biopsy technology for discovery of VOC biomarkers in early disease detection and precision medicine

Owlstone Medical, (diagnostics company developing a breathalyzer for disease), today announced the initiation of the PAN Cancer trial for Early Detection of Cancer in Breath. The large scale clinical study will evaluate the use of Owlstone Medical’s...

Billy Boyle, Founder and CEO of Owlstone Medical, (a diagnostics company developing a breathalyzer for disease), is to be awarded the Royal Academy of Engineering’s prestigious Silver Medal. The award recognizes engineer Billy’s work in spearheading the...

Billy Boyle, co-founder and CEO at Owlstone Medical, commented: “With over four decades’ work in cancer research we are honoured that Professor Sir Bruce Ponder is joining our SAB. His tremendous depth of experience and knowledge will...